<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Grief reaction &#8211; European Clinical Trials Information Network</title>
	<atom:link href="https://clinicaltrials.eu/meddra_pt/grief-reaction/feed/" rel="self" type="application/rss+xml" />
	<link>https://clinicaltrials.eu</link>
	<description>Bridging Patients with Clinical Trials</description>
	<lastBuildDate>Thu, 28 May 2026 11:28:27 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png</url>
	<title>Grief reaction &#8211; European Clinical Trials Information Network</title>
	<link>https://clinicaltrials.eu</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Study on the Effects of PEX010 Psilocybin Capsules for Patients with Prolonged Grief Disorder</title>
		<link>https://clinicaltrials.eu/trial/study-on-the-effects-of-pex010-psilocybin-capsules-for-patients-with-prolonged-grief-disorder/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 29 Apr 2026 15:05:52 +0000</pubDate>
				<guid isPermaLink="false">https://clinicaltrials.eu/trial/study-on-the-effects-of-pex010-psilocybin-capsules-for-patients-with-prolonged-grief-disorder/</guid>

					<description><![CDATA[This clinical trial is focused on studying the effects of a treatment for Prolonged Grief Disorder, a condition where individuals experience intense and persistent grief that disrupts their daily life. The treatment being tested is called PEX010 Psilocybin Capsules, which contain a substance derived from a type of mushroom known as Psilocybe cubensis. The study [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>This clinical trial is focused on studying the effects of a treatment for <i>Prolonged Grief Disorder</i>, a condition where individuals experience intense and persistent grief that disrupts their daily life. The treatment being tested is called <i>PEX010 Psilocybin Capsules</i>, which contain a substance derived from a type of mushroom known as <i>Psilocybe cubensis</i>. The study will use two different doses of the capsules: one with 1 mg of psilocybin and another with 25 mg of psilocybin.</p>
<p>The purpose of the study is to see if taking the <i>PEX010 Psilocybin Capsules</i> can help reduce the symptoms of prolonged grief disorder. Participants in the study will be randomly assigned to receive either the psilocybin capsules or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo during the trial.</p>
<p>Throughout the study, participants will have a dosing session where they will take the capsules. The researchers will then monitor the participants to see if there is a significant reduction in their grief symptoms, as measured by a specific scale used to assess prolonged grief disorder. The study aims to provide valuable information on whether psilocybin can be an effective treatment for those struggling with prolonged grief.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
